Facing the new diagnostic and treatment options of Alzheimer's disease: The necessity of informed consent
Alzheimer's & Dementia · 2025-01 · 21 (1)
DOI: 10.1002/alz.14204 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alzheimer's & Dementia, online erschienen am 30.12.2024. Verfasst von Jonas Karneboge und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychology, University of Siegen, Siegen, Germany. Hauptthemen laut MEDLINE: Alzheimer Disease, Decision Making, Informed Consent. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Demenz
Abstract (Originalsprache)
With advances in biomarker‐based detection of Alzheimer's disease (AD) and new treatment options with disease‐modifying treatments (DMTs), we are heading toward a new conceptualization of diagnostics and therapy in the early stages of AD. Yet consensus guidelines on best clinical practices in predictive AD diagnostics are still developing. Currently, there is a knowledge gap regarding counseling and disclosure practices in early symptomatic disease stages, its implications for dementia risk estimation, and DMTs with associated risks and benefits. The crucial feature is the capacity of patients with (mild) cognitive impairment, eligible for DMTs, to consent. This perspective aims to (1) discuss the current challenges in assessing capacity to consent and (2) highlight the importance of a supported (informed) decision‐making process. Measures to facilitate informed decision‐making of patients constitute an ethical approach to enhancing the quality of care in this evolving therapeutic landscape. Highlights This perspective: Explores biomarker‐based early symptomatic AD detection and the implications for patient care. Emphasizes supported decision‐making in DMTs for MCI and dementia patients. Discusses the need for standardized tools to assess the capacity to consent. Aligns diagnostic and treatment approaches with ethical care standards. Enhances patient autonomy in the evolving AD therapeutic landscape.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Psychology, University of Siegen, Siegen, Germany.
- Department of Psychiatry and Psychotherapy, University Medical Center, Johannes Gutenberg-University Mainz, Mainz, Germany.
- Department of Medical Ethics and History of Medicine, University Medical Center Goettingen, Goettingen, Germany.
- Department of Geriatric Psychiatry, Ökumenisches Hainich Klinikum gGmbH, Mühlhausen, Germany.
- Department of Psychiatry and Psychotherapy, University Medical Center Goettingen, Goettingen, Germany.
- Department of Psychiatry, University of Cologne, Medical Faculty, Cologne, Germany.
ORCID-Profile: Jonas Karneboge, Julia Haberstroh, Katharina Geschke, Julia Perry, Katrin Radenbach, Frank Jessen, Ayda Rostamzadeh
Zitieren
APA
Karneboge, J., Haberstroh, J., Geschke, K., Perry, J., Radenbach, K., Jessen, F., & Rostamzadeh, A. (2025). Facing the new diagnostic and treatment options of Alzheimer's disease: The necessity of informed consent. Alzheimer's & Dementia, 21(1). https://doi.org/10.1002/alz.14204
Vancouver
Karneboge J, Haberstroh J, Geschke K, Perry J, Radenbach K, Jessen F, et al. Facing the new diagnostic and treatment options of Alzheimer's disease: The necessity of informed consent. Alzheimer's & Dementia. 2025;21(1). doi:10.1002/alz.14204
BibTeX
@article{Karneboge2025,
author = {Karneboge, Jonas and Haberstroh, Julia and Geschke, Katharina and Perry, Julia and Radenbach, Katrin and Jessen, Frank and Rostamzadeh, Ayda},
title = {Facing the new diagnostic and treatment options of Alzheimer's disease: The necessity of informed consent},
journal = {Alzheimer's & Dementia},
year = {2025},
volume = {21},
number = {1},
doi = {10.1002/alz.14204}
}
EUVIMED